Yixintang Pharmaceutical Group Management

Management criteria checks 4/4

Yixintang Pharmaceutical Group's CEO ist Hong Xian Ruan , ernannt in Dec 2013, hat eine Amtszeit von 10.08 Jahren. besitzt direkt 30.58% der Aktien des Unternehmens, im Wert von CN¥4.39B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.1 Jahre bzw. 4.1 Jahre.

Key information

Hong Xian Ruan

Chief executive officer

CN¥1.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	10.3yrs
CEO ownership	30.6%
Management average tenure	4.4yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Mar 06

CEO

Hong Xian Ruan (57 yo)

10.3yrs

Tenure

CN¥1,000,000

Compensation

Mr. Hong Xian Ruan has been President and Non-Independent Director at Yixintang Pharmaceutical Group Co., Ltd. (formerly known as Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd.) since December 02, 201...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Hong Xian Ruan	President & Executive Chairman	10.3yrs	CN¥1.00m	30.58% CN¥ 3.5b
Sishun Dai	Chief Financial Officer	4.4yrs	CN¥500.00k	0.025% CN¥ 2.9m
Yong Zhang	Executive Director	4.4yrs	CN¥860.00k	0.053% CN¥ 6.1m
Guowei Ruan	Executive Director	4.4yrs	CN¥860.00k	0.049% CN¥ 5.6m
Zheng Hong Li	VP & Secretary	4.4yrs	CN¥500.00k	0.032% CN¥ 3.7m
Donglei Xiao	Accounting Supervisor	no data	no data	0.011% CN¥ 1.2m

4.4yrs

Average Tenure

45yo

Average Age

Erfahrenes Management: 002727Das Führungsteam des Unternehmens gilt als erfahren (4.1 Jahre durchschnittliche Betriebszugehörigkeit).

Board Members

Name	Position	Tenure	Compensation	Ownership
Hong Xian Ruan	President & Executive Chairman	10.4yrs	CN¥1.00m	30.58% CN¥ 3.5b
Yong Zhang	Executive Director	4.4yrs	CN¥860.00k	0.053% CN¥ 6.1m
Guowei Ruan	Executive Director	4.4yrs	CN¥860.00k	0.049% CN¥ 5.6m
Qiong Liu	Non-Independent Director	10.4yrs	CN¥100.80k	11.33% CN¥ 1.3b
Chunli Guo	Non-Independent Director	7.4yrs	CN¥860.00k	0.049% CN¥ 5.6m
Xiaohai Long	Independent Director	4.4yrs	CN¥120.00k	no data
Sitang Duan	Non-Employee Supervisor	4.4yrs	no data	no data
Xudong Chen	Independent Director	4.4yrs	CN¥120.00k	no data
Keyi Xu	Non-Independent Director	5.9yrs	no data	no data
Xianming Yang	Independent Director	4.4yrs	CN¥120.00k	no data
Ping Feng	Chairman of the Supervisory Board	4.4yrs	no data	no data
Wei Zhang	Supervisor	4.4yrs	no data	no data

4.4yrs

Average Tenure

54yo

Average Age

Erfahrener Vorstand: 002727Die Vorstandsmitglieder gelten als erfahren (4.1 Jahre durchschnittliche Amtszeit).

Yixintang Pharmaceutical Group Management

Management criteria checks 4/4

Key information

Recent management updates

Insufficient new directors

High number of new directors

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 20, 2022

Recent updates

Yixintang Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.92 (vs CN¥1.70 in FY 2022)

Return Trends At Yixintang Pharmaceutical Group (SZSE:002727) Aren't Appealing

Now 21% undervalued after recent price drop

Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Consensus revenue estimates decrease by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.40 in 2Q 2022)

Price target decreased by 8.1% to CN¥35.37

Yixintang Pharmaceutical Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023

Yixintang Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022

Full year 2022 earnings released: EPS: CN¥1.70 (vs CN¥1.56 in FY 2021)

Price target increased to CN¥38.51

Investor sentiment improved over the past week

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to CN¥33.64

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥40.40

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥46.85

High number of new directors

Yixintang Pharmaceutical Group Co., Ltd. Proposes Cash Dividend on A Shares for the Year 2021, Payable on April 29, 2022

Yixintang Pharmaceutical Group Co., Ltd. Approves Profit Distribution

Yixintang Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 20, 2022

Price target decreased to CN¥46.85

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.33 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.37 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.36 in 1Q 2020)

Price target increased to CN¥50.86

Investor sentiment improved over the past week

Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019)

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.06 in FY 2019)

New 90-day high: CN¥45.79

Yixintang Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥34.00

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.23

Laobaixing Reportedly in Merger Talks with Yixintang

Third quarter earnings released

New 90-day high - CN¥38.50

Price target raised to CN¥33.78

First half earnings released

Yixintang Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 19, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age